New Safety Concern Related To Antipsychotic Treatment
Philadelphia, PA, 1 December 2009 - Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia. In the current issue ofBiological Psychiatry, published by Elsevier, researchers discuss this cluster of metabolic side effects and how it may contribute to the risk for diabetes, hypertension, and other medical disorders associated with heart disease. This is of particular concern because there is a higher cardiovascular mortality among the severely mentally ill compared to the general population.
Researchers already know that differences exist between antipsychotics in their effect on clinical measures associated with cardiovascular risk, namely weight, lipids and glucose. Systemic inflammation has recently emerged as an important marker of cardiovascular risk, but the effects of antipsychotics on inflammatory markers in the blood have not been extensively studied until now.
Using data from the multi-center CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, funded by the National Institute of Mental Health, Jonathan Meyer and colleagues examined the impact of multiple antipsychotic therapies on changes in systemic inflammation. Their findings provide evidence that antipsychotic medications, particularly olanzapine (Zyprexa®, Eli Lilly and Co.) and quetiapine (Seroquel®, AstraZeneca), increase the levels of inflammation markers.
The markers implicated include C-reactive protein, E-selectin, and intercellular adhesion molecular-1 (ICAM-1). Increased levels of C-reactive protein in particular are associated with increased risk for the development or progression of many illnesses including heart disease, and stroke.
“This analysis provides the most compelling evidence to date that differences in antipsychotic metabolic liability are also seen with markers of systemic inflammation,” explained Dr. Meyer. “It also provides an impetus for monitoring cardiovascular risk markers in antipsychotic treated patients.”
Dr. John Krystal, the Editor of Biological Psychiatry, which is publishing this report, commented, “Doctors always try to balance the benefits and the risks associated with medications when making the decision to prescribe a particular medication to a particular patient. The more information that we have regarding the medical consequences of prescribing particular medications, the better the prescribing decisions can be.” Although this report does not provide any direct evidence linking the antipsychotic medications to these disorders, he added that “it is helpful to know that antipsychotic medications may contribute to inflammatory processes in the body and that these medications differ somewhat in producing this effect.”
Notes to Editors
The article is “Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study” by Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T. Scott Stroup, and Jeffrey A. Lieberman. The authors affiliations are as follows: From the Department of Psychiatry (JMM), University of California at San Diego; VA San Diego Healthcare System (JMM), San Diego, California; Department of Psychiatry (JPM), Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, Butner; Department of Biostatistics (VGD), Collaborative Studies Coordinating Center; Department of Psychiatry (TSS), University of North Carolina at Chapel Hill, Chapel Hill; Department of Psychiatry (MSS), Behavioral Sciences, Duke University Medical Center, Durham; Quintiles (SMD), Morrisville, North Carolina; Department of Psychiatry (DCG), Harvard University, Schizophrenia Program; General Hospital (DCG), Freedom Trail Clinic—Lindemann, Mental Health Center, Boston, Massachusetts; Neuroscience (HAN), University of Cincinnati, Cincinnati, Ohio; Adult Psychopharmacology Program (JKH), Division of Services and Interventions Research, National Institute of Mental Health, Bethesda, Maryland; and the Department of Psychiatry (JAL), Columbia University, Psychiatric Institute, New York, New York.
The article appears in Biological Psychiatry, Volume 66, Issue 11 (December 1, 2009), published by Elsevier.
The authors’ disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at email@example.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry is ranked 4th out of the 101 Psychiatry titles and 14th out of 219 Neurosciences titles on the 2008 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+1 215 239 3674